Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZYN002 Drug Interaction Study in Healthy Adults
NCT06930872Phase 1Completed
- Sponsor
- Harmony Biosciences
- Start
- Jun 2025
- Primary completion
- Oct 2025
- Countries
- 1
01
Overview
Phase 1, open-label trial of Zygel in Fragile X syndrome (FXS) and epilepsy, sponsored by Harmony Biosciences. Primary endpoints: Maximum measured plasma concentration of probe substrates and metabolites, Maximum measured plasma concentration of repaglinide and metabolite and 5 more. Started Jun 2025; status: completed.
02
Drugs
Zygel
03
Conditions
Fragile X syndrome (FXS)epilepsy
Beyond the preview
Go deeper on NCT06930872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06930872.